Hemophilia – a Congenital Blood Disorder Enabling Normal Functioning

Hemophilia is a rare, genetically determined coagulation disorder characterized by impaired blood clotting, resulting in prolonged and excessive bleeding episodes compared to healthy individuals. The condition arises from a deficiency of specific clotting proteins—namely, factor VIII in hemophilia A (the classical form) or factor IX in hemophilia B (also known as Christmas disease). These deficiencies stem from mutations in genes located on the X chromosome, rendering hemophilia an X-linked recessive disorder that predominantly affects males, while females often serve as asymptomatic carriers. Historical records suggest that symptoms resembling hemophilia were documented as early as antiquity, though the term "hemophilia" was not formally introduced into medical literature until 1828 by Swiss physician Friedrich Hopff. The disorder earned the moniker "royal disease" due to its transmission through Queen Victoria of England, who passed the mutated gene to her descendants, thereby spreading the condition among European royal families. For centuries, the excessive bleeding observed in affected individuals was erroneously attributed to fragile blood vessels—it was not until the scientific breakthroughs of the 1960s, when individual clotting factors were identified, that the underlying pathophysiology became clear. Prior to modern hematological advancements, patients with severe hemophilia often succumbed to internal hemorrhages damaging vital organs or endured debilitating joint and muscle bleeds, leading to chronic pain and disability. A pivotal milestone in treatment was the development of lyophilized clotting factor concentrates, which—owing to their stability under domestic storage conditions—dramatically enhanced patient prognosis and quality of life. Contemporary epidemiological estimates indicate that hemophilia occurs in approximately 1 in 10,000 male births globally, affecting roughly 400,000 individuals, with hemophilia A accounting for about 80% of all diagnosed cases.

Hemophilia represents a genetic disorder originating from abnormalities in the DNA sequences that encode critical proteins involved in the blood coagulation cascade. Because the defective gene is located on the X chromosome, its transmission follows sex-linked inheritance patterns, resulting in a markedly higher prevalence among males. Females typically serve as asymptomatic carriers of the mutated allele, though in rare instances they may also exhibit clinical symptoms. Notably, the genes responsible for producing clotting factor VIII (hemophilia A) and factor IX (hemophilia B) demonstrate an elevated susceptibility to spontaneous mutations in their nucleotide sequences. This genetic instability can lead to the emergence of the disease in offspring even within families that have no prior history of hemophilia. It is also important to emphasize that the condition manifests globally, irrespective of ethnic background, geographic location, or phenotypic characteristics of the affected populations.

In cases where offspring are conceived by a hemophiliac father and a genetically unaffected mother, none of the male descendants will exhibit clinical manifestations of the disorder, whereas all female descendants will inherit the mutated allele in a heterozygous state, thereby becoming carriers. These carrier women may subsequently transmit the defective gene to their own progeny, resulting in a 50% likelihood that their sons will be born with the fully symptomatic form of hemophilia or that their daughters will likewise become carriers of the faulty genetic material. Notably, some carriers may present with mild yet detectable phenotypic traits associated with impaired blood coagulation.

The clinical manifestations of hemophilia are contingent upon the severity of the condition; however, regardless of whether the disorder is type A or type B, the symptomatic presentation remains consistent across both variants. Among the most prevalent indicators are: a pronounced susceptibility to extensive subcutaneous bruising (ecchymosis) and hematoma formation, recurrent intra-articular hemorrhages resulting in joint swelling, acute pain, and reduced mobility, as well as spontaneous bleeding episodes occurring without identifiable external triggers. Additionally, affected individuals experience prolonged bleeding following invasive procedures—such as surgical operations—or even minor mechanical trauma, including lacerations. In cases of mild hemophilia, symptoms may remain latent until provoked by a significant event, such as major trauma or elective medical intervention; prior to such triggers, the disorder may exhibit no discernible signs, effectively remaining asymptomatic. The frequency and severity of hemorrhagic episodes are directly proportional to the deficiency of the respective clotting factor (factor VIII in hemophilia A or factor IX in hemophilia B) in the patient’s bloodstream.

The pathogenesis of acquired hemophilia involves circulating autoantibodies (inhibitors) directed against coagulation factor VIII, which neutralize its procoagulant function despite normal genetic production by the patient's cells. While the precise molecular trigger is not always apparent, autoantibody formation strongly correlates with underlying autoimmune connective tissue disorders (such as systemic lupus erythematosus or rheumatoid arthritis), hematological malignancies, solid tumors, or the postpartum state. Unlike congenital hemophilia, the acquired form rarely presents with recurrent hemarthroses in major joints; instead, extensive hematomas in deep soft tissues, skin, muscles, retroperitoneum, and gastrointestinal tract predominate, with intracranial hemorrhage posing an acute life-threatening emergency. Therapeutic management requires rapid hemostatic control utilizing bypass agents (recombinant activated factor VII or activated prothrombin complex concentrates) alongside prompt immunosuppressive regimens aimed at eliminating the pathogenic autoantibodies.

The fundamental objective of haemophilia treatment is to prevent bleeding episodes and to manage them effectively when they occur. The standard approach involves replenishing deficient clotting factors through the administration of high-purity concentrates. In individuals with mild to moderate haemophilia type A, desmopressin (commonly referred to as DDAVP) may be administered to elevate factor VIII levels to between three and six times the baseline concentration, thereby facilitating the control of active bleeding. Additionally, patients are advised to engage in regular physical exercise to maintain optimal fitness levels while avoiding high-risk sports that carry an elevated potential for traumatic injury.

Hemophilia is a lifelong, congenital bleeding disorder, yet the rapid progression of medical science has rendered it highly manageable through targeted and individualized therapeutic strategies. Clinical evidence and specialist observations confirm that patients diagnosed with this condition—particularly those adhering to proactive regimens such as regular prophylactic factor replacement therapy—can achieve a life expectancy comparable to that of the general population, provided the disorder is identified early and managed with precision. Furthermore, groundbreaking advancements, including home-based self-administration of clotting factor concentrates and telehealth monitoring, significantly mitigate complication risks, reduce hospitalization rates, and lower the overall economic burden of treatment, thereby substantially enhancing patients’ long-term well-being and daily functioning.